Manhattan Scientifics Cancer Imaging Asset Announces Progress on Australian Clinical Study

Rhea-AI Summary

Manhattan Scientifics Inc. (OTC: QB) holds over 50 million shares of Imagion Biosystems (IBX.AX), focused on developing advanced non-radioactive cancer imaging technology. A televised interview with Imagion's CEO, Bob Proulx, is highlighted, discussing their innovative diagnostic solutions aimed at early cancer detection. The press release emphasizes the partnership and technology transfer efforts with Los Alamos and Sandia National Laboratories in New Mexico. The company warns that investments are high risk, with future results uncertain, stressing forward-looking statements are not guarantees of performance.

NEW YORK--(BUSINESS WIRE)-- Manhattan Scientifics Inc. (OTC: QB), initially funded and is the current owner of more that 50 million shares of Imagion Biosystems Ltd. (IBX.AX).

Here we provide the reader with a televised interview with Imagion's CEO Bob Proulx. Stock Down Under Interview with Bob Proulx

About Manhattan Scientifics, Inc.
Manhattan Scientifics Inc. (www.mhtx.com) is focused on technology transfer and commercialization of transformative technologies. It has assisted incubating and financing closely with Science Teams at the Los Alamos National Laboratory and the Sandia National Laboratory in New Mexico

About Imagion Biosystems
Imagion Biosystems (www.imagionbiosystems.com)is developing a new non-radioactive and super-sensitive diagnostic imaging technology for very early detection of cancers. Imagion is listed on the Australian Stock Exchange (ASX).

Forward-looking statement
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005319/en/

Manhattan Scientifics, Inc.

Manny Tsoupanarias, 917-688-4158

Manny@mhtx.com

Or

Marvin Maslow, 917-923-3300

Marvin@mhtx.com

Source: Manhattan Scientifics Inc.

FAQ

What technology is Manhattan Scientifics involved with?

Manhattan Scientifics is involved in technology transfer and commercialization, particularly with Imagion Biosystems, which is developing non-radioactive diagnostic imaging technology for early cancer detection.

Who is the CEO of Imagion Biosystems?

The CEO of Imagion Biosystems is Bob Proulx, as mentioned in a televised interview highlighted in the press release.

What is the significance of Imagion's technology?

Imagion's technology aims for very early detection of cancers through a super-sensitive imaging technique, which is significant for improving patient outcomes.

What are the risks associated with investing in Manhattan Scientifics?

The press release states that purchasing shares of Manhattan Scientifics should be considered high risk, as there are uncertainties affecting future performance.

How many shares does Manhattan Scientifics own in Imagion Biosystems?

Manhattan Scientifics Inc. owns more than 50 million shares of Imagion Biosystems.